A Phase 1 Study of BBO-10203 in People With Advanced Solid Tumors

Full Title

Purpose

Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):

• Breast cancer that makes an excess amount of the HER2 protein.
• Breast cancer that is negative for HER2 but is fueled by estrogen and/or progesterone.
• Non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS gene.
• Colorectal cancer with a KRAS mutation.

BBO-10203 may slow or stop cancer growth by blocking the interaction between two proteins. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have one of the cancers listed above that continues to grow despite treatment.
• Have recovered from the serious side effects of prior therapies before taking BBO-10203.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.